Medicines Citation, commencement and interpretation 1 1 This Order may be cited as the Medicines (Miscellaneous Amendments) Order 2011 and shall come into force on 1st July 2011. 2 In this Order— “the Act” means the Medicines Act 1968; “the Pharmacy and General Sale Order” means the Medicines (Pharmacy and General Sale-Exemption) Order 1980 ; “the POM Order” means the Prescription Only Medicines (Human Use) Order 1997 . Amendment of Schedule 1 to the Pharmacy and General Sale Order 2 1 Schedule 1 to the Pharmacy and General Sale Order (exemptions for certain persons from sections 52 and 53) is amended as follows. 2 In Part 1, item 1A — a in column 1, after “chiropodists” insert “and podiatrists”; b for sub-paragraph (a) in column 2, substitute the following— a The following prescription only medicines— i Amorolfine hydrochloride cream where the maximum strength of the Amorolfine in the cream does not exceed 0.25 per cent by weight in weight; ii Amorolfine hydrochloride lacquer where the maximum strength of Amorolfine in the lacquer does not exceed 5 per cent by weight in volume; iii Amoxicillin; iv Co-Codamol; v Co-dydramol 10/500 tablets; vi Codeine Phosphate; vii Erythromycin; viii Flucloxacillin; ix Silver Sulfadiazine; x Tioconazole 28%; xi Topical hydrocortisone where the maximum strength of the hydrocortisone in the medicinal product does not exceed 1 per cent by weight in weight; and ; c for the entry in column 3, substitute— 1A The sale or supply shall be only in the course of their professional practice, and the medicinal product must have been made up for sale or supply in a container elsewhere than at the place at which it is sold or supplied. . Amendment of Schedule 5 to the POM Order 3 1 Schedule 5 to the POM Order (exemption for certain persons from section 58(2) of the Act) is amended as follows. 2 In Part 1 (exemption from restrictions on sale or supply)— a in item 4 — i in column 2, omit “Ergometrine maleate”, “Lidocaine” and “Lidocaine Hydrochloride”; ii in column 3, omit the words after “professional practice”; b in item 5 — i for the entry in column 2 substitute— 5 Items which are— a prescription only medicines which are not for parenteral administration and which— i are eye drops and are prescription only medicines by reason only that they contain not more than 0.5 per cent of Chloramphenicol, or ii are eye ointments and are prescription only medicines by reason only that they contain not more than 1.0 per cent Chloramphenicol, or iii are prescription only medicines by reason only that they contain any of the following substances— aa Cyclopentolate hydrochloride; bb Fusidic Acid; cc Tropicamide; b the following prescription only medicines— i Amorolfine hydrochloride cream where the maximum strength of the Amorolfine in the cream does not exceed 0.25 per cent by weight in weight; ii Amorolfine hydrochloride lacquer where the maximum strength of Amorolfine in lacquer does not exceed 5 per cent by weight in volume; iii Amoxicillin; iv Co-Codamol; v Co-dydramol 10/500 tablets; vi Codeine Phosphate; vii Erythromycin; viii Flucloxacillin; ix Silver Sulfadiazine; x Tioconazole 28%; xi Topical hydrocortisone where the maximum strength of hydrocortisone in the medicinal product does not exceed 1 per cent by weight in weight. ; ii for the entry in column 3 substitute— 5 The sale or supply shall be subject to the presentation of an order signed by— a a registered optometrist for a medicine listed under item 5(a) in column 2; b a registered chiropodist or podiatrist for a medicine listed under item 5(b) in column 2. ; c in item 10 — i in column 1, after “chiropodists” insert “or podiatrists”; ii for the entry in column 2, substitute— 10 The following prescription only medicines— a Amorolfine hydrochloride cream where the maximum strength of the Amorolfine in the cream does not exceed 0.25 per cent by weight in weight; b Amorolfine hydrochloride lacquer where the maximum strength of Amorolfine in lacquer does not exceed 5 per cent by weight in volume; c Amoxicillin; d Co-Codamol; e Co-dydramol 10/500 tablets; f Codeine Phosphate; g Erythromycin; h Flucloxacillin; i Silver Sulfadiazine; j Tioconazole 28%; k Topical hydrocortisone where the maximum strength of hydrocortisone in the medicinal product does not exceed 1 per cent by weight in weight. ; iii in column 3, omit the words after “professional practice”. 3 In Part 3 (exemptions from restriction on administration)— a in item 1 — i in column 1, after “chiropodists” insert “or podiatrists”; ii in column 2, omit “, as the sole active ingredient, not more than one of the following substances”; iii in column 3, after “practice” insert “and where the medicine includes a combination of substances listed under item 1 in column 2, those substances shall not be combined by the chiropodist or podiatrist”; b in item 2 — i in column 1, after “midwives” insert “and student midwives”; ii in the list of substances in column 2— aa for “cyclizine hydrochloride” substitute “cyclizine lactate”; bb omit “Haemaccel”; iii for the entry in column 3 substitute— 2 The medicine shall— a in the case of Lignocaine, Lignocaine hydrochloride and Promazine hydrochloride, be administered only while attending on a woman in childbirth, and b where administration is— i by a registered midwife, be administered in the course of their professional practice; ii by a student midwife— aa be administered under the direct supervision of a registered midwife; and bb not include Diamorphine, Morphine or Pethidine hydrochloride. . Signed by authority of the Secretary of State for Health. Earl Howe Parliamentary Under-Secretary of State, Department of Health 19th May 2011 Edwin Poots Minister for Health, Social Services and Public Safety 24th May 2011